IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Previously Presented): A heterocyclic compound represented by the formula I or a pharmaceutically acceptable salt thereof:

$$\begin{array}{c|c}
R_1 \\
R_2 \\
R_4 \\
R_5
\end{array}$$
...(I)

wherein

X represents a nitrogen atom or CH;

R₁ represents a halogen atom or hydroxyl;

R₂ represents a hydrogen atom, hydroxyl or amino;

 R_3 represents morpholino (which may be substituted with one or two C_1 - C_6 alkyl), pyrrolidinyl (which may be substituted with hydroxy C_1 - C_6 alkyl), or NR_6R_7 [wherein R_6 represents C_1 - C_6 alkyl and R_7 represents piperidinyl (which may be substituted with C_1 - C_6 alkyl)];

R₄ and R₅ each independently represent a hydrogen atom or C₁-C₆ alkyl;

with the proviso that R_2 is hydrogen atom and R_3 is pyrrolidinyl (which may be substituted with hydroxy C_1 - C_6 alkyl) when R_1 is hydroxyl.

Claim 2 (Previously Presented): The compound according to claim 1, wherein R_1 is chloro.

Claim 3 (Previously Presented): The compound according to claim 1, wherein R_1 is chloro and R_2 is amino.

Claim 4 (Previously Presented): The compound according to claim 1, wherein R_1 is chloro, R_2 is amino, R_3 is dimethylmorpholino, R_4 and R_5 each are hydrogen atom and X is nitrogen atom.

Claim 5 (Previously Presented): The compound according to claim 1, wherein R_1 is chloro and R_2 is hydroxyl.

Claim 6 (Previously Presented): The compound according to claim 1, wherein R_1 is chloro, R_2 is hydroxyl, R_3 is morpholino, R_4 and R_5 each are hydrogen atom and X is nitrogen atom.

Claim 7 (Previously Presented): The compound according to claim 1, wherein R_1 is hydroxyl, R_2 is hydrogen atom and R_3 is pyrrolidinyl (which may be substituted with hydroxymethyl).

Claim 8 (Currently Amended): The compound according to claim 1, wherein the compound represented by the formula I is:

2-(2-difluoromethyl-4-hydroxybenzimidazol-1-yl)-4-(2-hydroxymethylpyrrolidin-1-yl)-6-morpholinopyrimidine,

2-(6-amino-4-chloro-2-difluoromethylbenzimidazol-1-yl)-4-(2,2-dimethylmorpholino)-6-morpholino-1,3,5-triazine,

Application No. 10/532,245
Response to Official Action mailed May 12, 2006

2-(6-amino-4-chloro-2-difluoromethylbenzimidazol-1-yl)-4-(2-hydroxymethylpyrrolidin-1-yl)-6-morpholino-1,3,5-triazine,

2-(6-amino-4-chloro-2-difluoromethylbenzimidazol-1-yl)-4-[methyl(1-methylpiperidin-4-yl)amino]-6-morpholino-1,3,5-triazine,

2-(2-difluoromethyl-4-hydroxybenzimidazol-1-yl)-4-(2-hydroxymethylpyrrolidin-1-yl)-6-morpholino-1,3,5-triazine, or

2-(4-chloro-2-difluoromethyl-5-hydroxybenzimidazol-1-yl)-4,6-dimorpholino-1,3,5-triazine.

Claim 9 (Previously Presented): The compound according to claim 1, wherein the compound represented by the formula I is 2-(2-difluoromethyl-4-hydroxybenzimidazol-1-yl)-4-(2-hydroxymethylpyrrolidin-1-yl)-6-morpholino-1,3,5-triazine.

Claim 10 (Cancelled)

Claim 11 (Previously Presented): A pharmaceutical composition including comprising:

the compound of Claim 1, and

at least one pharmaceutically acceptable diluent or carrier.

Claim 12 (Previously Presented): A method for treating human breast cancer, comprising administering to a subject in need thereof an effective amount of the compound of Claim 1 or a pharmaceutically acceptable salt thereof.

Application No. 10/532,245

Response to Official Action mailed May 12, 2006

Claim 13 (Previously Presented): A method for treating human lung cancer, comprising administering to a subject in need thereof an effective amount of the compound of Claim 1 or a pharmaceutically acceptable salt thereof.

Claim 14 (Previously Presented): A method for treating human colon cancer, comprising administering to a subject in need thereof an effective amount of the compound of Claim 1 or a pharmaceutically acceptable salt thereof.

Claim 15 (Previously Presented): The compound of Claim 1, wherein X is a nitrogen atom.

Claim 16 (Previously Presented): The compound of Claim 1, wherein X is CH.

Claim 17 (Previously Presented): The compound of Claim 1, wherein R₁ represents a halogen atom.

Claim 18 (Previously Presented): The compound of Claim 1, wherein R₂ represents a hydrogen atom.

Claim 19 (Previously Presented): The compound of Claim 1, wherein R₂ represents hydroxyl.

Claim 20 (Previously Presented): The compound of Claim 1, wherein R₂ represents amino.

Application No. 10/532,245 Response to Official Action mailed May 12, 2006

Claim 21 (Previously Presented): The compound of Claim 1, wherein R_3 represents morpholino (which may be substituted with one or two C_1 - C_6 alkyl).

Claim 22 (Previously Presented): The compound of Claim 1, wherein R_3 represents pyrrolidinyl (which may be substituted with hydroxy C_1 - C_6 alkyl).

Claim 23 (Previously Presented): The compound of Claim 1, wherein R_3 represents NR_6R_7 [wherein R_6 represents C_1 - C_6 alkyl and R_7 represents piperidinyl (which may be substituted with C_1 - C_6 alkyl)].